X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/03/2857229/0/en/AB-Science-announces-that-Health-Canada-has-granted-eligibility-for-reconsideration-request-for-masitinib-in-ALS.html
https://www.globenewswire.com//news-release/2024/03/13/2845340/0/en/AB-Science-New-research-shows-that-masitinib-limits-neuronal-damage-in-a-model-of-neuroimmune-driven-neurodegenerative-disease.html
https://www.globenewswire.com//news-release/2024/02/26/2835372/0/en/AB-Science-announces-that-Health-Canada-has-issued-a-Notice-of-Non-Compliance-Withdrawal-NON-w-for-masitinib-in-ALS.html
https://www.globenewswire.com//news-release/2024/01/26/2818214/0/en/AB-Science-announces-an-update-in-the-marketing-authorization-application-of-masitinib-in-amyotrophic-lateral-sclerosis-at-the-European-Medicines-Agency.html
https://www.globenewswire.com//news-release/2024/01/15/2809319/0/en/AB-Science-receives-notice-of-allowance-for-European-patent-covering-masitinib-until-2036-in-the-treatment-of-mastocytosis.html
https://www.globenewswire.com//news-release/2023/11/28/2787283/0/en/AB-Science-will-host-a-live-webcast-on-Thursday-November-30-2023-from-3pm-to-4pm-CET-to-present-the-masitinib-development-program-in-sickle-cell-disease.html
https://www.globenewswire.com/news-release/2023/06/26/2694707/0/en/AB-Science-receives-Notice-of-Allowance-for-European-patent-covering-masitinib-in-the-treatment-of-metastatic-castrate-refractory-prostate-cancer-mCRPC.html
https://www.globenewswire.com/news-release/2023/06/01/2680654/0/en/AB-Science-announces-issuance-of-a-Canadian-patent-for-masitinib-in-the-treatment-of-ALS-with-protection-until-2037.html
https://www.globenewswire.com/news-release/2023/04/12/2645623/0/en/AB-Science-Results-of-masitinib-in-ALS-selected-for-a-scientific-platform-presentation-at-the-AAN-2023-including-long-term-survival-analysis-and-a-new-analysis-of-patient-populatio.html
https://www.globenewswire.com/news-release/2023/04/04/2641085/0/en/AB-Science-announces-that-it-has-submitted-its-response-to-the-day-120-questions-in-the-EMA-regulatory-review-of-masitinib-in-amyotrophic-lateral-sclerosis-and-clarifies-the-new-ti.html
https://www.globenewswire.com/news-release/2022/12/29/2580809/0/en/AB-Science-has-received-approval-from-the-U-S-Food-and-Drug-Administration-FDA-to-initiate-the-confirmatory-Phase-3-study-with-masitinib-in-the-treatment-of-progressive-multiple-sc.html
https://www.globenewswire.com//news-release/2022/12/27/2579973/0/en/Masitinib-receives-orphan-drug-status-for-the-treatment-of-amyotrophic-lateral-sclerosis-in-Switzerland.html
https://www.globenewswire.com/news-release/2022/12/13/2573089/0/en/AB-Science-receives-Notice-of-Deficiency-NOD-from-Health-Canada-for-masitinib-in-the-treatment-of-amyotrophic-lateral-sclerosis-ALS.html
https://www.globenewswire.com//news-release/2022/11/21/2560193/0/en/AB-Science-receives-U-S-Food-and-Drug-Administration-FDA-authorization-to-initiate-confirmatory-Phase-3-clinical-study-with-masitinib-in-the-treatment-of-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2022/10/10/2531253/0/en/AB-Science-receives-first-agencies-authorizations-to-initiate-confirmatory-Phase-3-clinical-study-with-masitinib-in-the-treatment-of-Alzheimer-s-disease.html
https://www.globenewswire.com/news-release/2022/06/07/2458060/0/en/AB-Science-today-announced-publication-of-results-from-its-positive-study-of-masitinib-in-severe-asthma-uncontrolled-by-oral-corticosteroids-in-the-peer-reviewed-Journal-of-Asthma-.html
https://www.globenewswire.com/news-release/2022/05/26/2451639/0/en/AB-Science-announces-that-Health-Canada-has-started-the-review-of-New-Drug-Submission-for-masitinib-in-the-treatment-of-ALS.html
https://www.globenewswire.com/news-release/2022/02/22/2389667/0/en/AB-Science-announces-the-publication-of-the-masitinib-positive-pivotal-Phase-3-trial-in-progressive-forms-of-multiple-sclerosis-in-the-journal-Neurology-Neuroimmunology-Neuroinflam.html
https://www.globenewswire.com/news-release/2022/02/21/2388751/0/en/AB-Science-announces-that-Health-Canada-has-granted-authorization-to-file-a-New-Drug-Submission-for-masitinib-in-the-treatment-of-ALS-under-the-Notice-of-Compliance-with-Conditions.html
https://www.globenewswire.com/news-release/2022/01/03/2360203/0/en/AB-Science-granted-authorization-to-initiate-confirmatory-Phase-III-trial-of-masitinib-in-progressive-forms-of-multiple-sclerosis-by-the-French-Health-Authority-ANSM.html
https://www.globenewswire.com/news-release/2021/11/29/2342468/0/en/AB-Science-announces-dosing-of-first-patient-in-Phase-2-trial-of-masitinib-s-antiviral-activity-against-the-SARS-CoV-2-COVID-19-virus.html
https://www.globenewswire.com/news-release/2021/11/18/2337748/0/en/AB-Science-received-authorization-from-the-FDA-to-resume-patient-enrollment-in-the-confirmatory-Phase-3-study-of-masitinib-AB19001-in-patients-with-ALS.html
https://www.globenewswire.com/news-release/2021/10/04/2308166/0/en/AB-Science-receives-FDA-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-MCAS.html
https://www.biospace.com/article/releases/ab-science-receives-fda-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-mcas-/?s=71
https://www.globenewswire.com/news-release/2021/10/04/2308166/0/en/AB-Science-receives-FDA-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-MCAS.html
https://www.biospace.com/article/releases/ab-science-receives-fda-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-mcas-/?s=71
https://www.clinicaltrialsarena.com/news/ab-science-phase-ii-covid-19-trial-masitinib/
https://www.globenewswire.com/news-release/2021/09/20/2300050/0/en/AB-Science-announced-that-an-abstract-on-the-long-term-survival-of-masitinib-in-ALS-has-been-selected-for-a-platform-presentation-at-the-Annual-Meeting-of-the-Spanish-Society-of-Ne.html
https://www.globenewswire.com/news-release/2021/09/14/2296980/0/en/AB-Science-announced-that-it-has-received-new-authorizations-to-resume-patient-enrollment-in-its-Phase-3-studies-of-masitinib.html
https://www.globenewswire.com/news-release/2021/09/13/2296002/0/en/AB-Science-announced-today-that-results-from-masitinib-study-AB12003-in-prostate-cancer-have-been-presented-at-the-2021-American-Urological-Association.html
https://www.globenewswire.com/news-release/2021/08/25/2286575/0/en/AB-Science-announces-that-it-has-received-a-second-authorization-to-resume-patient-enrollment-in-the-Phase-3-study-of-masitinib-in-mastocytosis.html
https://www.globenewswire.com/news-release/2021/08/23/2285051/0/en/AB-Science-announces-that-it-has-received-the-first-authorization-to-resume-patient-enrollment-in-the-confirmatory-Phase-3-study-of-masitinib-AB19001-in-ALS.html
https://www.ab-science.com/results-from-masitinib-study-ab12005-in-pancreatic-cancer-have-been-presented-at-the-2021-asco-annual-meeting/
https://www.globenewswire.com/news-release/2021/06/08/2243242/0/en/AB-Science-is-providing-a-summary-of-the-live-webcast-held-on-June-3-2021-following-the-voluntary-hold-in-the-clinical-studies-of-masitinib.html
http://www.globenewswire.com/fr/news-release/2020/12/04/2139619/0/en/AB-Science-announces-that-confirmatory-Phase-3-study-AB12005-with-masitinib-in-first-line-pancreatic-cancer-with-pain-was-successful.html#:~:text=Study%20AB12005%20was%20a%20confirmatory,masitinib%20as%20compared%20to%20control.
https://www.globenewswire.com/news-release/2020/10/20/2111361/0/en/AB-Science-announces-positive-top-line-Phase-3-results-for-oral-masitinib-in-severe-asthma.html
https://www.globenewswire.com/news-release/2020/07/08/2059048/0/en/AB-Science-announces-that-new-results-published-in-the-peer-reviewed-Journal-of-Alzheimer-s-Disease-support-masitinib-s-potential-mode-of-action-in-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2020/05/06/2028392/0/en/AB-Science-granted-authorization-by-ANSM-to-initiate-Phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-the-treatment-of-COVID-19.html
https://www.globenewswire.com/news-release/2020/02/20/1988146/0/en/AB-Science-announces-positive-top-line-Phase-2B-3-results-for-oral-masitinib-in-progressive-forms-of-multiple-sclerosis.html
https://ml-eu.globenewswire.com/Resource/Download/828c7f54-34c5-4a29-b77c-3a28a225e7ee
https://ml-eu.globenewswire.com/Resource/Download/828c7f54-34c5-4a29-b77c-3a28a225e7ee
https://ml-eu.globenewswire.com/Resource/Download/828c7f54-34c5-4a29-b77c-3a28a225e7ee
https://www.fiercebiotech.com/orion-take-repurposed-heart-failure-drug-into-phase-3-for-als
http://www.pharmatimes.com/news/ab_sciences_decides_against_re-examination_of_masitinib_filing_1237342
http://www.pharmatimes.com/news/chmp_rejects_ab_sciences_als_drug_1232829
http://www.in-pharmatechnologist.com/Regulatory-Safety/EMA-cmttee-says-Masitinib-should-not-be-approved-due-to-GCP-failings
http://www.in-pharmatechnologist.com/Regulatory-Safety/AB-Science-suspends-French-masitinib-trials-after-ANSM-finds-deviations
http://www.pmlive.com/pharma_news/ab_science_claims_first_with_motor_neurone_disease_therapy_1189658
http://www.pharmatimes.com/news/experimental_als_drug_wins_eu_orphan_status_1093509
Market Place
Share 
